Science

This cholesterol drug promised to be a game-changer. Why did it flop in the clinic — and is there still hope?

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 03/11/2026, 11:35:25 UTC.

Briefings

A clinical trial involving physicians and a specific cholesterol drug failed to demonstrate cardiovascular benefits, prompting researchers to investigate why the therapy did not work despite initial excitement. The study involved a limited number of participants and was published in November 2026, leaving many questions about the drug's efficacy and future development unanswered.

Key points

• A clinical trial involving physicians failed to show a benefit for a cholesterol drug that targets lipoprotein(a) levels.
• The study was published in November 2026 in Nature, with a DOI of 10.1038/d41586-026-03504-2.

Context

Physicians were excited about several therapies that slash levels of lipoprotein(a), an important cardiovascular risk factor. This trial failure highlights a significant gap in current treatments for this specific risk factor.

Limitations

The evidence is limited to a single failed trial with no additional data on long-term outcomes or alternative therapies. The study was published in November 2026, and the specific number of participants and exact sample size are not provided in the source.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 15/11/2026, 08:51:39 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeialufs6mqmw7w3cc6evbssggkf633n2hj2gavmr4373ib5eiuuu2a